BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fang QQ, Huang WJ, Li XY, Cheng YH, Tan MJ, Liu J, Wei HJ, Meng Y, Wang DY. Effectiveness of favipiravir (T-705) against wild-type and oseltamivir-resistant influenza B virus in mice. Virology 2020;545:1-9. [PMID: 32174453 DOI: 10.1016/j.virol.2020.02.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Qin J, Lin J, Zhang X, Yuan S, Zhang C, Yin Y. Evaluation of the Clinical Effectiveness of Oseltamivir for Influenza Treatment in Children. Front Pharmacol 2022;13:849545. [PMID: 35462914 DOI: 10.3389/fphar.2022.849545] [Reference Citation Analysis]
2 Abas AH, Tallei TE, Fatimawali F, Celik I, Alhumaydhi FA, Emran TB, Dhama K, Rabaan AA, Garout MA, Halwani MA, Al Mutair A, Alhumaid S, Harapan H. 4’-fluorouridine and its derivatives as potential COVID-19 oral drugs: a review. F1000Res 2022;11:410. [DOI: 10.12688/f1000research.109701.1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Giri S, Sen S, Singh R, Paul P, Sahu R, Nandi G, Dua TK. Current challenges in different approaches to control COVID-19: a comprehensive review. Bull Natl Res Cent 2022;46. [DOI: 10.1186/s42269-022-00730-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Fakhri S, Nouri Z, Moradi SZ, Akkol EK, Piri S, Sobarzo-Sánchez E, Farzaei MH, Echeverría J. Targeting Multiple Signal Transduction Pathways of SARS-CoV-2: Approaches to COVID-19 Therapeutic Candidates. Molecules 2021;26:2917. [PMID: 34068970 DOI: 10.3390/molecules26102917] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
5 Yang C, Huang Y, Liu S. Therapeutic Development in COVID-19. Adv Exp Med Biol 2021;1318:435-48. [PMID: 33973193 DOI: 10.1007/978-3-030-63761-3_25] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Vicenti I, Zazzi M, Saladini F. SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19. Expert Opin Ther Pat 2021;31:325-37. [PMID: 33475441 DOI: 10.1080/13543776.2021.1880568] [Cited by in Crossref: 10] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
7 Chilamakuri R, Agarwal S. COVID-19: Characteristics and Therapeutics. Cells 2021;10:206. [PMID: 33494237 DOI: 10.3390/cells10020206] [Cited by in Crossref: 27] [Cited by in F6Publishing: 60] [Article Influence: 27.0] [Reference Citation Analysis]
8 Lipin R, Dhanabalan AK, Gunasekaran K, Solomon RV. Piperazine-substituted derivatives of favipiravir for Nipah virus inhibition: What do in silico studies unravel? SN Appl Sci 2021;3:110. [PMID: 33458565 DOI: 10.1007/s42452-020-04051-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Liu X, Liu C, Liu G, Luo W, Xia N. COVID-19: Progress in diagnostics, therapy and vaccination. Theranostics 2020;10:7821-35. [PMID: 32685022 DOI: 10.7150/thno.47987] [Cited by in Crossref: 77] [Cited by in F6Publishing: 62] [Article Influence: 38.5] [Reference Citation Analysis]
10 Jiang C, Yao X, Zhao Y, Wu J, Huang P, Pan C, Liu S, Pan C. Comparative review of respiratory diseases caused by coronaviruses and influenza A viruses during epidemic season. Microbes Infect. 2020;22:236-244. [PMID: 32405236 DOI: 10.1016/j.micinf.2020.05.005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 15.0] [Reference Citation Analysis]
11 Yousefi B, Valizadeh S, Ghaffari H, Vahedi A, Karbalaei M, Eslami M. A global treatments for coronaviruses including COVID-19. J Cell Physiol 2020;235:9133-42. [PMID: 32394467 DOI: 10.1002/jcp.29785] [Cited by in Crossref: 27] [Cited by in F6Publishing: 48] [Article Influence: 13.5] [Reference Citation Analysis]